Quali sono gli orari di apertura?

Lunedì 09:00 - 18:00 Martedì 09:00 - 18:00 Mercoledì 09:00 - 18:00 Giovedì 09:00 - 18:00 Venerdì 09:00 - 18:00

Haematologica

Casa
Italia
Pavia
Haematologica

www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recommendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

18/09/2025

Acute myeloid leukemia-associated mutations influence the biology of hematopoietic cells during the pre-leukemic phase, and could sustain leukemic stem cell (LSC) quiescence through modulation of dormant and active states of the LSC with a critical role for extended self-renewal in pre-leukemic hematopoietic stem cells. A new study sheds light on the cooperation of nucleophosmin 1 (NPM1) gene mutations and internal tandem duplications (ITD) of the fms-related tyrosine kinase 3 (FLT3) gene in LSC.
https://haematologica.org/article/view/11973

16/09/2025

Review Series on pediatric acute leukemias and myelodysplastic syndromes: pediatric myelodysplastic syndromes (MDS) represent a rare group of clonal hematopoietic stem cell disorders accounting for approximately 5% of pediatric hematologic malignancies. Find here a detailed overview of classification systems, the germline and somatic genetic landscapes and their clinical implications in pediatric MDS.
https://haematologica.org/article/view/12132

14/09/2025

Review Series on pediatric acute leukemias and myelodysplastic syndromes: pediatric acute myeloid leukemia (AML) has a unique genomic background characterized by frequent chromosomal translocations – a new review summarizes the current state of pediatric AML classifications in the context of a new classification framework based on the findings of updated genomic profiling.
https://haematologica.org/article/view/11895

13/09/2025

Review Series on pediatric acute leukemias and myelodysplastic syndromes: everything you need to know about KMT2A-rearranged acute lymphoblastic leukemia in infants, progress in treatment, drug-related toxicity, the implementation of less toxic agents, acquired drug resistance, central nervous system involvement, lineage switches and an overview on preclinical models that can assist in guiding new treatment strategies.
https://haematologica.org/article/view/12017

11/09/2025

Review Series on pediatric acute leukemias and myelodysplastic syndromes: we are entering a new era in which almost all children with T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T-ALL/LBL) are cured. Find here a comprehensive review on risk factors for relapse of T-ALL/T-LBL, established treatment regimens, promising small molecule inhibitors and immunotherapies with the potential to revolutionize the treatment of relapsed/refractory T-ALL/LBL.
https://haematologica.org/article/view/11894

09/09/2025

Review Series on pediatric acute leukemias and myelodysplastic syndromes: acute and chronic therapy-related toxicities can affect treatment effectiveness, overall survival, and patients’ quality of life. This review highlights six key acute toxicities associated with acute lymphoblastic leukemia treatment: venous thromboembolism, osteonecrosis, neurological complications, delayed methotrexate clearance, asparaginase-induced pancreatitis, and adverse effects linked to novel biological therapies.
https://haematologica.org/article/view/11963

07/09/2025

Find here a new review series of Haematologica on pediatric acute leukemias and myelodysplastic syndromes focusing on the challenges in a field in which much progress has been made during the last decades.
https://doi.org/10.3324/haematol.2024.286783

06/09/2025

Read the new review about uncommon subtypes of BCR::ABL1-positive chronic myelogenous leukemia (CML):
- BCR::ABL1-positive thrombocythemia;
- neutrophilic BCR::ABL1-positive CML;
- m-bcr (p190BCR-ABL1) variant of CML;
- eosinophilic predominant CML;
- smoldering BCR::ABL1-positive CML;
https://haematologica.org/article/view/12065

04/09/2025

Landmark paper in Hematology: in 2015, David Steensma et al. established the framework for the definition of clonal hematopoiesis of indeterminate potential and proposed an updated diagnostic schema for myelodysplastic syndromes.
https://haematologica.org/article/view/12232

01/09/2025

September 2025 issue is available online. See and download for free the Haematologica Digital Edition! https://haematologica.org/preview/digital/110/9

27/08/2025

Shortage of skilled cytogenetic technologists? Read here about the proposal of a new workflow integrating multiple fluorescence in situ hybridization panels, genomic microarray, next-generation sequencing panel-based gene mutation profiling and RNA fusion testing.
https://haematologica.org/article/view/11924

24/08/2025

New data from a retrospective study help to uncover the impact of obesity on pegaspargase pharmacokinetics, the probability of asparaginase-related toxicities, and treatment efficacy in children with acute lymphoblastic leukemia.
https://haematologica.org/article/view/11941

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì	09:00 - 18:00
Martedì	09:00 - 18:00
Mercoledì	09:00 - 18:00
Giovedì	09:00 - 18:00
Venerdì	09:00 - 18:00

Telefono

+39038227129

Sito Web

http://www.haematologica.org/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

Vuoi che la tua studio sia il Clinica più quotato a Pavia?